HK1184854A1 - 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物 - Google Patents

貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物

Info

Publication number
HK1184854A1
HK1184854A1 HK13112206.0A HK13112206A HK1184854A1 HK 1184854 A1 HK1184854 A1 HK 1184854A1 HK 13112206 A HK13112206 A HK 13112206A HK 1184854 A1 HK1184854 A1 HK 1184854A1
Authority
HK
Hong Kong
Prior art keywords
treatment
breast cancer
blood plasma
combination therapies
plasma biomarkers
Prior art date
Application number
HK13112206.0A
Other languages
English (en)
Inventor
Haas Sanne Lysbet De
Paul Delmar
Dorothee Foernzler
Ursula Klause
Stefan Scherer
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1184854A1 publication Critical patent/HK1184854A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK13112206.0A 2010-07-19 2013-10-30 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物 HK1184854A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10170008 2010-07-19
PCT/EP2011/062232 WO2012010552A1 (en) 2010-07-19 2011-07-18 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Publications (1)

Publication Number Publication Date
HK1184854A1 true HK1184854A1 (zh) 2014-01-30

Family

ID=44545675

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13112206.0A HK1184854A1 (zh) 2010-07-19 2013-10-30 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物
HK16105145.5A HK1217093A1 (zh) 2010-07-19 2013-10-30 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16105145.5A HK1217093A1 (zh) 2010-07-19 2013-10-30 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物

Country Status (15)

Country Link
US (3) US20130121999A1 (zh)
EP (2) EP2596363B1 (zh)
JP (1) JP6055764B2 (zh)
KR (1) KR20130091750A (zh)
CN (2) CN103109188B (zh)
AU (1) AU2011281706A1 (zh)
BR (1) BR112013001423A2 (zh)
CA (1) CA2804350A1 (zh)
ES (1) ES2619590T3 (zh)
HK (2) HK1184854A1 (zh)
MX (1) MX343801B (zh)
NZ (1) NZ603780A (zh)
RU (1) RU2013106938A (zh)
SG (1) SG187013A1 (zh)
WO (1) WO2012010552A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2558931C2 (ru) * 2010-01-12 2015-08-10 Нестек С.А. Способы предсказания ответа трижды негативного рака молочной железы на терапию
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AR089067A1 (es) * 2011-12-05 2014-07-30 Hoffmann La Roche Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama
US9116159B2 (en) 2012-05-22 2015-08-25 Regeneron Pharmaceuticals, Inc. VEGF-A121 assay
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CA2963091A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016094273A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
KR20190080825A (ko) 2016-03-21 2019-07-08 다나-파버 캔서 인스티튜트 인크. T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도
US9950070B2 (en) 2016-08-16 2018-04-24 Korea University Research And Business Foundation HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
KR102247908B1 (ko) 2020-10-08 2021-05-06 주식회사 엠디엡투스 Her2 압타머-항암 약물 복합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806989A1 (de) 1998-02-19 1999-08-26 Roche Diagnostics Gmbh Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
EP1575416B1 (en) * 2002-07-19 2013-10-02 Beth Israel Deaconess Medical Center Methods of diagnosing pre-eclampsia
DE102004029909A1 (de) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern
US20090010887A1 (en) * 2004-10-06 2009-01-08 Ben-Sasson Shmuel A Method and composition for enhancing anti-angiogenic therapy
WO2007059094A2 (en) * 2005-11-14 2007-05-24 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US9675578B2 (en) * 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
WO2008088854A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
EP2125016A2 (en) * 2007-02-01 2009-12-02 Genetech, Inc. Combination therapy with angiogenesis inhibitors
EP2065399A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy
CN102016579B (zh) * 2007-11-30 2015-04-08 健泰科生物技术公司 Vegf多态性和抗血管发生疗法
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
KR101596539B1 (ko) * 2008-12-23 2016-02-22 제넨테크, 인크. 암 환자에서의 진단 목적용 방법 및 조성물

Also Published As

Publication number Publication date
CN103109188B (zh) 2015-11-25
EP2596363A1 (en) 2013-05-29
US20130183303A1 (en) 2013-07-18
NZ603780A (en) 2015-04-24
US20130121999A1 (en) 2013-05-16
AU2011281706A1 (en) 2013-01-10
BR112013001423A2 (pt) 2016-05-24
EP3156800A1 (en) 2017-04-19
MX2013000673A (es) 2013-02-27
JP6055764B2 (ja) 2016-12-27
CA2804350A1 (en) 2012-01-26
CN103109188A (zh) 2013-05-15
CN105327347A (zh) 2016-02-17
HK1217093A1 (zh) 2016-12-23
EP2596363B1 (en) 2017-01-18
MX343801B (es) 2016-11-23
WO2012010552A1 (en) 2012-01-26
US20130183302A1 (en) 2013-07-18
ES2619590T3 (es) 2017-06-26
KR20130091750A (ko) 2013-08-19
JP2013534308A (ja) 2013-09-02
SG187013A1 (en) 2013-02-28
RU2013106938A (ru) 2014-08-27

Similar Documents

Publication Publication Date Title
HK1184854A1 (zh) 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物
HK1254859A1 (zh) 治療乳腺癌的方法
HK1201413A1 (zh) 乳癌的治療
ZA201403602B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
IL228738A0 (en) Antibodies for cancer treatment
EP2542081A4 (en) COMPOSITIONS FOR CANCER TREATMENT
HK1202253A1 (zh) 癌症的聯合治療
ZA201300218B (en) Treatment of blood cancer
HK1181459A1 (zh) 貝伐單抗組合療法用於治療胰腺癌的血漿生物標誌物
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
HRP20181757T1 (hr) Kombinirana terapija za liječenje raka dojke
EP2608671A4 (en) COMPOUNDS USED IN THE TREATMENT OF CANCER
IL275636A (en) Medical combination for cancer treatment
HK1202334A1 (zh) 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物
WO2012106461A9 (en) Combination therapy for treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201017354D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200721